mGluR5 antagonists: Discovery, characterization and drug development

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 5, 2008, Pages 655-665

  Gasparini, F ^a   Bilbe, G ^a   Gomez Mancilla, B ^a   Spooren, W ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anxiety; Depression; Fragile X syndrome; Gastroesophageal reflux disorder; Metabotropic glutamate receptors; MPEP; Pain; Parkinson's disease

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; ABP 688; ADX 10059; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; DICLOFENAC; EGLUMETAD; FENOBAM; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; LY 393675; LY 404039; MEMANTINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; OLANZAPINE; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANXIETY; CLINICAL TRIAL; DEPRESSION; DRUG DOSE ESCALATION; EPILEPSY; FRAGILE X SYNDROME; GASTROESOPHAGEAL REFLUX; HUMAN; MIGRAINE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; PAIN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SPINOTHALAMIC TRACT; VALIDATION PROCESS;

ANIMALS; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; LIGANDS; MOLECULAR STRUCTURE; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN CONFORMATION; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 50249155962     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Sheldon AL, Robinson MB: The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int (2007) 51(6-7):333-355.
2. Nakanishi S: Molecular diversity of glutamate receptors and implications for brain function. Science (1992) 258(5082):597- 603.
3. Conn PJ: Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann NY Acad Sci (2003) 1003:12-21.
4. Wang SJ, Yang TT: Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders. Drug News Perspect (2005) 18(9):561-566.
5. Meldrum BS: Glutamate as a neurotransmitter in the brain: Review of physiology and pathology. J Nutr (2000) 130(4S Suppl):1007S-1015S.
6. Parsons CG, Stöffler A, Danysz W: Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology (2007) 53(6):699-723.
7. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD: Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology (2008) 33(7):1603-1610.
8. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN et al: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med (2007) 13(9):1102-1107.
9. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, Gentsch C: Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther (2000) 295(3):1267-1275. •• Describes the in vivo characterization of MPEP and its anxiolytic-like profile.
10. Dickenson AH, Chapman V, Green GM: The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharmacol (1997) 28(5):633-638.
11. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M: Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci (2002) 22(13):5669-5678.
12. Addex Pharmaceuticals Inc: Addex presents ADX10059 GERD data at conference. Press Release (2007) October 29.
13. Addex Pharmaceuticals Inc: Addex reports positive results in phase IIa clinical trial with ADX10059 in migraine. Press Release (2007) April 20.
14. 2+ signal transduction. J Biol Chem (1992) 267(19):13361-13368.
15. Hermans E, Challiss RA: Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: Prototypic family C G-protein-coupled receptors. Biochem J (2001) 359(3):465-484.
16. Pin JP, Galvez T, Prezeau L: Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther (2003) 98(3):325-354.
17. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, Morikawa K: Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (2000) 407(6807):971-977.
18. Muto T, Tsuchiya D, Morikawa K, Jingami H: Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc Natl Acad Sci USA (2007) 104(10):3759-3764.
19. Romano C, Yang WL, O'Malley KL: Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem (1996) 271(45):28612- 28616.
20. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N: Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett (1993) 163(1):53-57.
21. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW: Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol (1995) 355(3):455-469.
22. Shigemoto R, Mizuno N: Metabotropic glutamate receptors - immunocytochemical and in situ hybridization analyses. In: Handbook of Chemical Neuroanatomy: Glutamate. Ottersen OP, Storm-Mathisen J (Eds), Elsevier Amsterdam, Amsterdam, The Netherlands (2000):63-98.
23. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH: Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse (2005) 57(3):123-131.
24. Mitrano DA, Smith Y: Comparative analysis of the subcellular and subsynaptic localization of mGluR1a and mGluR5 metabotropic glutamate receptors in the shell and core of the nucleus accumbens in rat and monkey. J Comp Neurol (2007) 500(4):788-806.
25. Tebano MT, Martire A, Rebola N, Pepponi R, Domenici MR, Gro MC, Schwarzschild MA, Chen JF, Cunha RA, Popoli P: Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: A possible key mechanism in the modulation of N-methyl-D-aspartate effects. J Neurochem (2005) 95(4):1188-1200.
26. Spooren W, Gasparini F: mGlu5 receptor antagonists: A novel class of anxiolytics? Drug News Perspect (2004) 17(4):251-257.
27. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD: Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov (2005) 4(2):131-144.
28. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, Troost D: Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: Opposite regulation of glutamate transporter proteins. Eur J Neurosci (2003) 17(10):2106-2118.
29. Valenti O, Conn PJ, Marino MJ: Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors co-expressed in the same neuronal populations. J Cell Physiol (2002) 191(2):125-137.
30. 2+- and protein kinase C-dependent pathway. J Neurochem (2005) 93(1):232-245.
31. Enz R: The trick of the tail: Protein-protein interactions of metabotropic glutamate receptors. Bioessays (2007) 29(1):60-73.
32. Kim CH, Lee J, Lee JY, Roche KW: Metabotropic glutamate receptors: Phosphorylation and receptor signaling. J Neurosci Res (2008) 86(1):1-10.
33. Schoepp DD, Jane DE, Monn JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology (1999) 38(10):1431-1476.
34. Baker SR, Clark BP, Harris JR, Griffy KI, Kingston AE, Tizzano JP: LY393675, an alpha-substituted-cyclobutylglycine, is a potent group I metabotropic glutamate receptor antagonist. Soc Neurosci Abstr (1998) 24(Part 1):Abst 229.17.
35. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR et al: Design, synthesis, and pharmacological characterization of (+)-2- aminobicyclo[3.1.0]hexane-2,6- dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem (1997) 40(4):528-537.
36. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL Jr, Wright RA, Johnson BG, Andis SL et al: Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem (1999) 42(6):1027-1040.
37. Daggett LP, Sacaan AI, Akong M, Rao SP, Hess SD, Liaw C, Urrutia A, Jachec C, Ellis SB, Dreessen J, Knöpfel T et al: Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5. Neuropharmacology (1995) 34(8):871-886.
38. Velicelebi G, Stauderman KA, Varney MA, Akong M, Hess SD, Johnson EC: Fluorescence techniques for measuring ion channel activity. Methods Enzymol (1999) 294:20-47.
39. Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F et al: SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther (1999) 290(1):170-181.
40. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA et al: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology (1999) 38(10):1493-1503. • Describes the identification and characterization of MPEP, the first selective allosteric antagonist of mGluR5.
41. Jaeschke G, Wettstein JG, Nordquist RE, Spooren W: mGlu5 receptor antagonists and their therapeutic potential. Expert Opin Ther Patents (2008) 18(2):123-142. • A comprehensive review on allosteric negative modulators of mGluR5.
42. Porter RH, Jaeschke G, Spooren W, Ballard TM, Büttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, Mühlemann A et al: Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther (2005) 315(2):711-721.
43. Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D, Gasparini F, Kuhn R, Nicoletti F, Flor PJ: Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology (2000) 39(12):2223-2230.
44. Szydlowska K, Kaminska B, Baude A, Parsons CG, Danysz W: Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol (2007) 554(1):18-29.
45. Tizzano JP, Griffey KI, Schoepp DD: Induction or protection of limbic seizures in mice by mGluR subtype selective agonists. Neuropharmacology (1995) 34(8):1063-1067.
46. Chapman AG, Nanan K, Williams M, Meldrum BS: Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6- methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology (2000) 39(9):1567-1574.
47. Nagaraja RY, Grecksch G, Reymann KG, Schroeder H, Becker A: Group I metabotropic glutamate receptors interfere in different ways with pentylenetetrazole seizures, kindling, and kindling-related learning deficits. Naunyn SchmiedebergsArch Pharmacol (2004) 370(1):26-34.
48. Moldrich RX, Chapman AG, De Sarro G, Meldrum BS: Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur J Pharmacol (2003) 476(1-2):3-16.
49. Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, Gasparini F, Spooren W, Stoehr N, Pagano A, Flor PJ et al: Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology (2001) 40(1):1-9.
50. Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, Schmid P, Gasparini F, Kuhn R, Urban L: mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology (2001) 40(1):10-19.
51. Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch JJ III, Wade CL, Decker MW, Honore P: Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol (2004) 506(2):107-118.
52. Addex Pharmaceuticals Inc: Addex Pharmaceuticals first half 2007 financial results. Press Release (2007) July 25.
53. Wiley JL, Cristello AF, Balster RL: Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur J Pharmacol (1995) 294(1):101-107.
54. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry (1996) 29(1):23-26.
55. Danysz W, Parsons AC: Glycine and N-methyl-D- aspartate receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev (1998) 50(4):597-664.
56. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol (1999) 375(1-3):31-40.
57. Pilc A, Kłodzińska A, Brański P, Nowak G, Pa?ucha A, Szewczyk B, Tatarczyńska E, Chojnacka-Wójcik E, Wierońska JM: Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology (2002) 43(2):181-187.
58. Nordquist RE, Steckler T, Wettstein JG, Mackie C, Spooren W: Metabotropic glutamate receptor modulation, translational methods, and biomarkers: Relationships with anxiety. Psychopharmacology (2008) 199(3):389-402.
59. Tatarczyńska E, Klodzińska A, Chojnacka-Wójcik E, Palucha A, Gasparini F, Kuhn R, Pilc A: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol (2001) 132(7):1423-1430.
60. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY: Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol (2007) 17(3):172-179.
61. Li X, Need AB, Baez M, Witkin JM: Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther (2006) 319(1):254-249.
62. Itil TM, Seaman BA, Huque M, Mukhopadhyay S, Blasucci D, Nq KT, Ciccone PE: The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: An open rising dose tolerance and efficacy study. Curr Ther Res (1978) 24(6):708-724.
63. Pecknold JC, McClure DJ, Appeltauer L: Fenobam in anxious out-patients. Curr Ther Res (1980) 27(1):119-123.
64. Lapierre YD, Oyewumi LK: Fenobam: Another anxiolytic? Curr Ther Res (1982) 31(1):95-101.
65. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T: Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol (1982) 2(2):129-133.
66. Friedman CTH, Davis LJ, Ciccone PE, Rubin RT: Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377) versus placebo. Curr Ther Res (1980) 27(2):144-151.
67. Spooren WP, Gasparini F, Bergmann R, Kuhn R: Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol (2000) 406(3):403-410.
68. Ossowska K, Konieczny J, Wolfarth S, Wierońska J, Pilc A: Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology (2001) 41(4):413-420.
69. Samadi P, Grégoire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bédard PJ, Di Paolo T: mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging (2007) 29(7):1040-1051.
70. Dent J: Gastro-oesophageal reflux disease. Digestion (1998) 59(5):433-445.
71. Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA: Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology (2005) 129(3):995-1004.
72. Jensen J, Lehmann A, Uvebrant A, Carlsson A, Jerndal G, Nilsson K, Frisby C, Blackshaw LA, Mattsson JP: Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol (2005) 519(1-2):154-157.
73. Young RL, Page AJ, O'Donnell TA, Cooper NJ, Blackshaw LA: Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5. Am J Physiol Gastrointest Liver Physiol (2007) 292(2):G501-G511.
74. Huber KM, Gallagher SM, Warren ST, Bear MF: Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA (2002) 99(11):7746-50.
75. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 27(7):370-377.
76. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP: Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology (2005) 49(7):1053-1066.
77. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF: Correction of fragile X syndrome in mice. Neuron (2007) 56(6):955-962.
78. Neuropharm Group plc: Commencement of phase II trial of NPL-2009 in fragile X syndrome. Press Release (2008) March 10.
79. Passchier J, Gee A, Willemsen A, Vaalburg W, van Waarde A: Measuring drug-related receptor occupancy with positron emission tomography. Methods (2002) 27(3):278-286.
80. Talbot PS, Laruelle M: The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol (2002) 12(6):503-511.
81. 3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett (2002) 12(3):407-409.
82. 3H]methoxyPyEP, an mGluR5 selective radioligand. Life Sci (2003) 73(3):371-379.
83. Hamill TG, Seiders TJ, Krause S, Ryan C, Sanabria S, Gibson RE, Patel S, Cosford N, Roppe J, Yang J, King C et al: Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. J Label Compd Radiopharm (2003) 46(Suppl 1):S184.
84. Yu M, Tueckmantel W, Wang X, Zhu A, Kozikowski AP, Brownell AL: Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynyl derivatives of pyridine: Synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors. Nucl Med Biol (2005) 32(6):631-640.
85. Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, Cosford ND, Roppe J, Kamenecka T, Patel S, Gibson RE et al: Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse (2005) 56(4):205-216.
86. 11C-ABP688. J Nucl Med (2007) 48(2):247-252. •• Describes the first clinically validated PET ligand for a glutamate receptor.
87. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl- D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 63(8):856-864.
88. ADDEX PHARMACEUTICALS SA (Bolea C, Mutel V, Rocher J-P, Bessi AS, Le Poul E): Novel aminopyridine derivatives as mGluR5 antagonists. WO-2004078728 (2004).
89. ADDEX PHARMACEUTICALS SA (Bessi AS, Bolea C, Bonnet B, Epping-Jordan M, Poirier N, Poli SM, Rocher JP, Thollon Y): Novel alkynyl derivatives as modulators of metabotropic glutamate receptors. WO-2005123703 (2005).
90. F HOFFMANN-LA ROCHE LTD (Buettelmann B, Ceccarelli SM, Jaeschke G, Kolczewski S, Porter R, Vieira E): Imidazol-4-yl-ethynyl-pyridine derivatives. WO-2004080998 (2004).
91. MERCK & CO INC (Cosford ND, Kamenecka T, Roppe JR): Imidazolyl and pyrazolyl ethyne compounds. US-2005085523 (2005).
92. ELI LILLY & CO (Agejas-Chicharro FJ, Dressman BA, Gutierrez Sanfeliciano S, Henry SS, Martinez Perez JA, Massey M, Monn JA, Zia-Ebrahimi MS): Pyridyl derivatives and their use as mGlu5 receptor antagonists. WO-2005094822 (2005).
93. NPS PHARMACEUTICALS INC (Van Wagenen BC, Stormann TM, Moe ST, Sheehan S, McLeod DA, Smith DL, Isaac MB, Slassi A): Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists. WO-01012627 (2001).
94. ASTRAZENECA AB/NPS PHARMACEUTICALS INC (Wensbo D, Xin T, Stefanac T, Arora J, Edwards L, Isaac MB, Slassi A, Stormann TM, Mcleod DA, Kers A, Malmberg J et al): New compounds. WO-2004014881 (2004).
95. F HOFFMANN-LA ROCHE LTD (Jaeschke G, Kolczewski S, Porter RHP, Schnider P, Vieira E): Thiazolo[4,5-c]pyridine derivatives. US-20070105891 (2007).
96. RICHTER GEDEON LTD (Keserü G, Wéber C, Bielik A, Bobok AA, Gál K, Meszlényiné Sipos M, Molnár L, Vastag M): Quinoline derivatives useful in the treatment of mGluR5 receptor-mediated disorders. WO-2007072093 (2007).